Equity Holdings 2 B.V. Pf Net Worth

What's Equity Pf's mailing address?

Equity's mailing address filed with the SEC is RIVIUM WESTLAAN 142, , CAPELLE AAN DEN LJSSEL, P7, 2909LD.

Insiders trading at Allogene Therapeutics Inc

Over the last 6 years, insiders at Allogene Therapeutics Inc have traded over $137,494,387 worth of Allogene Therapeutics Inc stock and bought 2,891,304 units worth $29,333,135 . The most active insiders traders include Group Holdings (Sbs) Adviso..., Arie Belldegrun и Inc Pfizer. On average, Allogene Therapeutics Inc executives and independent directors trade stock every 27 days with the average trade being worth of $286,894. The most recent stock trade was executed by Deborah M. Messemer on 18 June 2024, trading 18,641 units of ALLO stock currently worth $42,501.

What does Allogene Therapeutics Inc do?

allogene therapeutics is a biotechnology company with a mission to catalyze the next revolution in cancer treatment through the development of allogeneic chimeric antigen receptor t-cell (car t) therapy directed at blood cancers and solid tumors. founded and led by former kite pharma executives who bring unrivaled clinical development acumen in cell therapy, allogene is well-positioned to further the potential of allogeneic cell therapy for patients. allogeneic car t therapies are engineered from cells of healthy donors and stored for “off-the-shelf” use in patients. this approach eliminates the need to create personalized therapy from a patient’s own cells, simplifies manufacturing, and reduces the time patients must wait for car t treatment. the allogene portfolio includes 16 pre-clinical t cell therapy assets and ucart19, an allogeneic car t therapy currently in phase 1 development for the treatment of acute lymphoblastic leukemia (all). through its notable partnerships, allogene le

Allogene Therapeutics Inc executives and stock owners

Allogene Therapeutics Inc executives and other stock owners filed with the SEC include:

• David Chang,
  President, Chief Executive Officer, Co-Founder, Director
• Rafael Amado,
  Executive Vice President - Research and Development, Chief Medical Officer
• Arie Belldegrun,
  Executive Chairman of the Board
• Eric Schmidt,
  Chief Financial Officer
• Alison Moore,
  Chief Technical Officer
• Dr. David D. Chang M.D., Ph.D.,
  Co-Founder, Pres, CEO & Director
• Joshua Kazam,
  Co-Founder, Director
• Dr. Rafael G. Amado M.D.,
  Exec. VP of R&D
• Dr. Arie S. Belldegrun F.A.C.S., FACS, M.D.,
  Co-Founder & Exec. Chairman
• Dr. Arie S. Belldegrun F.A.C.S., M.D., FACS,
  Co-Founder & Exec. Chairman
• Dr. Rafael G. Amado,
  Chief Medical Officer and Exec. VP of R&D
• Dr. Alison Moore Ph.D.,
  Chief Technical Officer
• Dr. Eric Thomas Schmidt Ph.D.,
  Chief Financial Officer
• Veer Bhavnagri,
  Gen. Counsel & Compliance Officer
• Franz Humer,
  Independent Director
• Deborah Messemer,
  Independent Director
• Owen Witte,
  Independent Director
• Joshua A. Kazam,
  Co-Founder & Director
• Veer Bhavnagri,
  Chief Compliance Officer, General Counsel
• Todd Sisitsky,
  Independent Director
• John DeYoung,
  Independent Director
• David Bonderman,
  Lead Independent Director
• Stephen Cheng,
  Chief Information Officer
• David M. Tanen J.D.,
  Sec.
• Christine Cassiano,
  Chief Communications Officer
• Barbra Sasu,
  Chief Scientific Officer
• Timothy L. Moore,
  Chief Technical Officer
• Yinlin Jack Chen,
  SVP, Finance
• Inc Pfizer,
  10% owner
• Earl Martin Douglas,
  SVP, General Counsel
• Elizabeth A. Barrett,
  
• Vicki L Sato,
  
• Equity Holdings 2 B.V. Pf,
  10% owner
• Stephen Mayo,
  
• Zachary Roberts,
  EVP of R&D
• Lillian Smith,
  VP, Corporate Counsel
• Geoffrey M. Parker,
  CHIEF FINANCIAL OFFICER